Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients

Pinhas Cohen, Donna M. Peehl, Thomas A. Stamey, Kristin F. Wilson, David R. Clemmons, Ronald (Ron) Rosenfeld

Research output: Contribution to journalArticle

189 Citations (Scopus)

Abstract

We have previously documented the presence of specific insulin-like growth factor (IGF)-binding protein (IGFBPs) in seminal plasma and prostate epithelial cell-conditioned medium IGFBP-2 is the prevalent IGFBP in both fluids. To assess whether patients with prostate carcinoma have alterations in serum IGFP levels related to the production of IGFBPs by their tumors, we performed Western ligand blots (WLB) and IGFBP-2 RIA on serum samples from 32 patients with prostate carcinoma of various degrees of clinical severity and compared them to results in 16 healthy age-matched controls. We have also measured serum IGF-I and -II by RIA The mean level of IGFBP-2 in the prostate cancer patients was 170% of control levels by WLB analysis and 195% of control levels by RIA (P <0.01). The degree of elevation of IGFBP-2 was related to the stage of the tumor and the levels of the serum tumor marker, prostate-specific antigen. Serum IGFBP-3 levels determined by WLB and serum IGF-I and IGF-II levels measured by RIA after acid chromatography were not different among the subjects with cancer and the normal controls. We conclulde that IGFBP-2, which is the main IGFBP produced by prostate epithelial cells, is elevated in the serum of patients with prostate carcinoma, and that the degree of this elevation is related to serum prostate-specific antigen levels and the stage of the tumor. We speculate that prostate-derived IGFBPs may be secreted by prostate tumors and could e of value in understanding the pathophysiology of prostatic tumor growth as well as provide potential diagnostic markers.

Original languageEnglish (US)
Pages (from-to)1031-1035
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume76
Issue number4
StatePublished - Apr 1993
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor Binding Protein 2
Insulin-Like Growth Factor Binding Proteins
Tumors
Prostate
Prostatic Neoplasms
Serum
Level control
Prostate-Specific Antigen
Ligands
Insulin-Like Growth Factor I
Neoplasms
Insulin-Like Growth Factor II
Western Blotting
Carcinoma
Insulin-Like Growth Factor Binding Protein 3
Epithelial Cells
Tumor Biomarkers
Conditioned Culture Medium
Chromatography
Semen

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Cohen, P., Peehl, D. M., Stamey, T. A., Wilson, K. F., Clemmons, D. R., & Rosenfeld, R. R. (1993). Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. Journal of Clinical Endocrinology and Metabolism, 76(4), 1031-1035.

Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. / Cohen, Pinhas; Peehl, Donna M.; Stamey, Thomas A.; Wilson, Kristin F.; Clemmons, David R.; Rosenfeld, Ronald (Ron).

In: Journal of Clinical Endocrinology and Metabolism, Vol. 76, No. 4, 04.1993, p. 1031-1035.

Research output: Contribution to journalArticle

Cohen, P, Peehl, DM, Stamey, TA, Wilson, KF, Clemmons, DR & Rosenfeld, RR 1993, 'Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients', Journal of Clinical Endocrinology and Metabolism, vol. 76, no. 4, pp. 1031-1035.
Cohen, Pinhas ; Peehl, Donna M. ; Stamey, Thomas A. ; Wilson, Kristin F. ; Clemmons, David R. ; Rosenfeld, Ronald (Ron). / Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. In: Journal of Clinical Endocrinology and Metabolism. 1993 ; Vol. 76, No. 4. pp. 1031-1035.
@article{fe64e195da424a2d8de1589e045a50fa,
title = "Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients",
abstract = "We have previously documented the presence of specific insulin-like growth factor (IGF)-binding protein (IGFBPs) in seminal plasma and prostate epithelial cell-conditioned medium IGFBP-2 is the prevalent IGFBP in both fluids. To assess whether patients with prostate carcinoma have alterations in serum IGFP levels related to the production of IGFBPs by their tumors, we performed Western ligand blots (WLB) and IGFBP-2 RIA on serum samples from 32 patients with prostate carcinoma of various degrees of clinical severity and compared them to results in 16 healthy age-matched controls. We have also measured serum IGF-I and -II by RIA The mean level of IGFBP-2 in the prostate cancer patients was 170{\%} of control levels by WLB analysis and 195{\%} of control levels by RIA (P <0.01). The degree of elevation of IGFBP-2 was related to the stage of the tumor and the levels of the serum tumor marker, prostate-specific antigen. Serum IGFBP-3 levels determined by WLB and serum IGF-I and IGF-II levels measured by RIA after acid chromatography were not different among the subjects with cancer and the normal controls. We conclulde that IGFBP-2, which is the main IGFBP produced by prostate epithelial cells, is elevated in the serum of patients with prostate carcinoma, and that the degree of this elevation is related to serum prostate-specific antigen levels and the stage of the tumor. We speculate that prostate-derived IGFBPs may be secreted by prostate tumors and could e of value in understanding the pathophysiology of prostatic tumor growth as well as provide potential diagnostic markers.",
author = "Pinhas Cohen and Peehl, {Donna M.} and Stamey, {Thomas A.} and Wilson, {Kristin F.} and Clemmons, {David R.} and Rosenfeld, {Ronald (Ron)}",
year = "1993",
month = "4",
language = "English (US)",
volume = "76",
pages = "1031--1035",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients

AU - Cohen, Pinhas

AU - Peehl, Donna M.

AU - Stamey, Thomas A.

AU - Wilson, Kristin F.

AU - Clemmons, David R.

AU - Rosenfeld, Ronald (Ron)

PY - 1993/4

Y1 - 1993/4

N2 - We have previously documented the presence of specific insulin-like growth factor (IGF)-binding protein (IGFBPs) in seminal plasma and prostate epithelial cell-conditioned medium IGFBP-2 is the prevalent IGFBP in both fluids. To assess whether patients with prostate carcinoma have alterations in serum IGFP levels related to the production of IGFBPs by their tumors, we performed Western ligand blots (WLB) and IGFBP-2 RIA on serum samples from 32 patients with prostate carcinoma of various degrees of clinical severity and compared them to results in 16 healthy age-matched controls. We have also measured serum IGF-I and -II by RIA The mean level of IGFBP-2 in the prostate cancer patients was 170% of control levels by WLB analysis and 195% of control levels by RIA (P <0.01). The degree of elevation of IGFBP-2 was related to the stage of the tumor and the levels of the serum tumor marker, prostate-specific antigen. Serum IGFBP-3 levels determined by WLB and serum IGF-I and IGF-II levels measured by RIA after acid chromatography were not different among the subjects with cancer and the normal controls. We conclulde that IGFBP-2, which is the main IGFBP produced by prostate epithelial cells, is elevated in the serum of patients with prostate carcinoma, and that the degree of this elevation is related to serum prostate-specific antigen levels and the stage of the tumor. We speculate that prostate-derived IGFBPs may be secreted by prostate tumors and could e of value in understanding the pathophysiology of prostatic tumor growth as well as provide potential diagnostic markers.

AB - We have previously documented the presence of specific insulin-like growth factor (IGF)-binding protein (IGFBPs) in seminal plasma and prostate epithelial cell-conditioned medium IGFBP-2 is the prevalent IGFBP in both fluids. To assess whether patients with prostate carcinoma have alterations in serum IGFP levels related to the production of IGFBPs by their tumors, we performed Western ligand blots (WLB) and IGFBP-2 RIA on serum samples from 32 patients with prostate carcinoma of various degrees of clinical severity and compared them to results in 16 healthy age-matched controls. We have also measured serum IGF-I and -II by RIA The mean level of IGFBP-2 in the prostate cancer patients was 170% of control levels by WLB analysis and 195% of control levels by RIA (P <0.01). The degree of elevation of IGFBP-2 was related to the stage of the tumor and the levels of the serum tumor marker, prostate-specific antigen. Serum IGFBP-3 levels determined by WLB and serum IGF-I and IGF-II levels measured by RIA after acid chromatography were not different among the subjects with cancer and the normal controls. We conclulde that IGFBP-2, which is the main IGFBP produced by prostate epithelial cells, is elevated in the serum of patients with prostate carcinoma, and that the degree of this elevation is related to serum prostate-specific antigen levels and the stage of the tumor. We speculate that prostate-derived IGFBPs may be secreted by prostate tumors and could e of value in understanding the pathophysiology of prostatic tumor growth as well as provide potential diagnostic markers.

UR - http://www.scopus.com/inward/record.url?scp=0027413596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027413596&partnerID=8YFLogxK

M3 - Article

C2 - 7682560

AN - SCOPUS:0027413596

VL - 76

SP - 1031

EP - 1035

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -